Dissolution rate and stability study of flavanone aglycones, naringenin and hesperetin, by drug delivery systems based on polyvinylpyrrolidone (PVP) nanodispersions

References

• Havsteen B. (1983). Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol, 32:1141.
   PubMed Web of Science ®Google Scholar
• Kanaze FI, Gabrieli C, Kokkalou E, Georgarakis M, Niopas I. (2003). Simultaneous reversed-phase high-performance liquid chromatographic method for the determination of diosmin, hesperidin and naringin in different citrus fruit juices and pharmaceutical formulations. J Pharm Biomed Anal, 33:243.
   PubMed Web of Science ®Google Scholar
• Vinson JA, Liang X, Proch J, Hontz BA, Dancel J, Sandone N. (2002). Polyphenol antioxidants in citrus juices: In vitro and in vivo studies relevant to heart disease. Adv Exp Med Biol, 505:113.
   PubMed Web of Science ®Google Scholar
• Acker FA, Schouten O, Haenen GR, van der Vijgh WJ, Bast A. (2000). Flavonoids can replace alpha-tocopherol as an antioxidant. FEBS Lett, 473:145.
   PubMed Web of Science ®Google Scholar
• Borradaile NM, Carroll KK, Kurowska EM. (1999). Regulation of HepG2 cell apolipoprotein B metabolism by the citrus flavanones hesperetin and naringenin. Lipids, 34:591.
   PubMed Web of Science ®Google Scholar
• Lee SH, Park YB, Bae KH, Bok SH, Kwon YK, Lee ES, . (1999). Cholesterol-lowering activity of naringenin via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase and acyl coenzyme A: Cholesterol acyltransferase in rats. Ann Nutr Metab, 43:173.
   PubMed Web of Science ®Google Scholar
• Santos KF, Oliveira TT, Nagem TJ, Pinto AS, Oliveira MG. (1999). Hypolipidaemic effects of naringenin, rutin, nicotinic acid and their associations. Pharmacol Res, 40:493.
   PubMed Web of Science ®Google Scholar
• Choe SC, Kim HS, Jeong TS, Bok SH, Park YB. (2001). Naringin has an antiatherogenic effect with the inhibition of intercellular adhesion molecule-1 in hypercholesterolemic rabbits. J Cardiovasc Pharmacol, 38:947.
   PubMed Web of Science ®Google Scholar
• Middleton Jr E, Kandaswami C. (1992). Effects of flavonoids on immune and inflammatory cell functions. Biochem Pharmacol, 43:1167.
   PubMed Web of Science ®Google Scholar
• Crespo ME, Gálvez J, Ocete MA, Zarzuelo A. (1999). Anti-inflammatory activity of diosmin and hesperidin in rat colitis induced by TNBS. Planta Medica, 65:651.
   PubMed Web of Science ®Google Scholar
• Manthey JA. (2000). Biological properties of flavonoids pertaining to inflammation. Microcirculation, 7:S29.
   PubMed Web of Science ®Google Scholar
• So FV, Guthrie N, Chambers AF, Moussa M, Carroll KK. (1996). Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr Cancer, 26:167.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Makita H, Kawabata K, Mori H, Kakumoto M, Satoh K, . (1997). Chemoprevention of azoxymethane-induced rat colon carcinogenesis by the naturally occurring flavonoids, diosmin and hesperidin. Carcinogenesis, 18:957.
   PubMed Web of Science ®Google Scholar
• Ghosal A, Satoh H, Thomas PE, Bush E, Moore D. (1996). Inhibition and kinetics of cytochrome P450 3A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos, 24:940.
   PubMed Web of Science ®Google Scholar
• Kanaze FI, Kokkalou E, Niopas I, Georgarakis M, Stergiou A, Bikiaris D. (2006). Dissolution enhancement of flavonoids by solid dispersions in PVP and PEG matrixes, a comparative study. J Appl Polym Sci, 102:460.
   Web of Science ®Google Scholar
• Kanaze FI, Kokkalou E, Niopas I, Georgarakis M, Stergiou A, Bikiaris D. (2006). Thermal analysis study of flavonoid solid dispersions having enhanced solubility. J Therm Anal Cal, 83:283.
   Web of Science ®Google Scholar
• Chiou WL, Riegelman S. (1971). Pharmaceutical applications of solid dispersion systems. J Pharm Sci, 60:1281.
   PubMed Web of Science ®Google Scholar
• Ford JL. (1986). The current status of solid dispersions. Pharm Acta Helv, 61:69.
   PubMedGoogle Scholar
• Van dem Mooter G, Wuyts M, Blaton N, Busson R, Grobet P, Augustijns P, . (2001). Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur J Pharm Sci, 12:261.
   PubMed Web of Science ®Google Scholar
• Yu L. (2001). Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv Drug Deliv Rev, 4:27.
   Google Scholar
• Damian F, Blaton N, Kinget R, Van den Mooter G. (2002). Physical stability of solid dispersions of the antiviral agent UC-781 with PEG 6000, Gelucire 44/14 and PVP K30. Int J Pharm, 244:87.
   PubMed Web of Science ®Google Scholar
• Yoshinari T, Forbes RT, York P, Kawashima Y. (2003). Crystallisation of amorphous mannitol is retarded using boric acid. Int J Pharm, 258:109.
   PubMed Web of Science ®Google Scholar
• Duclos R, Grenet J, Saiter JM, Besancon P, Orecchioni AM. (1990). Effect of aging on progesterone-poly(ethylene glycol) 6000 dispersions. X-ray study. Drug Dev Ind Pharm, 16:255.
   Web of Science ®Google Scholar
• Saers ES, Nystrom C, Alden M. (1993). Physicochemical aspects of drug release. XVI. The effect of storage on drug dissolution from solid dispersions and the influence of cooling rate and incorporation of surfactant. Int J Pharm, 90:105.
   Web of Science ®Google Scholar
• Hancock BC, Zografi G. (1997). Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci, 86:1.
   PubMed Web of Science ®Google Scholar
• Doherty C, York P. (1989). Accelerated stability of an X-ray amorphous furosemide-polyvinylpyrrolidone solid dispersion. Drug Dev Ind Pharm, 15:1969.
   Web of Science ®Google Scholar
• Guillaume F, Guyot-Herman AM, Duclos R, Besancuon P, Orechioni AM, Drache M, . (1991). Elaboration and physical study of an oxodipine solid dispersion in order to formulate tablets. Drug Dev Ind Pharm, 18:811.
   Web of Science ®Google Scholar
• Taylor LS, Zografi G. (1997). Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res, 14:1691.
   PubMed Web of Science ®Google Scholar
• Kanaze FI, Kokkalou E, Georgarakis M, Niopas I. (2004). Validated high-performance liquid chromatographic method utilizing solid-phase extraction for the simultaneous determination of naringenin and hesperetin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci, 801:363.
   PubMed Web of Science ®Google Scholar
• Najib N, Suleiman M. (1985). The kinetics of drug release from ethyl cellulose solid dispersions. Drug Dev Ind Pharm, 11:2169.
   Web of Science ®Google Scholar
• Singh P, Desai SJ, Simonelli AP, Higuchi WI. (1967). Release rates of solid drug mixtures dispersed in inert matrices I. Non disintegrating discs. J Pharm Sci, 56:1542.
   PubMed Web of Science ®Google Scholar
• Desai SJ, Singh P, Simonelli AP, Higuchi WI. (1966). Investigation of factors influencing release of solid drug dispersed in wax matrices. III. Quantitative studies involving polyethylene plastic matrix. J Pharm Sci, 55:1230.
   PubMed Web of Science ®Google Scholar
• Higuchi T. (1963). Mechanism of sustained action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci, 52:1145.
   PubMed Web of Science ®Google Scholar
• Hixson AW, Crowell JH. (1931). Dependence of reaction velocity upon surface and agitation (I) theoretical consideration. Ind Eng Chem, 23:923.
   Google Scholar
• Abdou HM. (1989). Theory of dissolution. In: Gennaro A, Migdalof B, Hassert GL, Medwick T, eds. Dissolution, bioavailability and bioequivalence. Pennsylvania: MACK Publishing, 11–36.
   Google Scholar
• Paulo C, Jose MSL. (2001). Modeling and comparison of dissolution profiles. Eur J Pharm Sci, 13:123.
   PubMed Web of Science ®Google Scholar
• Hancock BC, Zografi G. (1994). The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm Res, 11:471.
   PubMed Web of Science ®Google Scholar
• Fukuoka E, Makita M, Yamamura S. (1986). Some physicochemical properties of glassy indomethacin. Chem Pharm Bull, 34:4314.
   PubMed Web of Science ®Google Scholar
• Yoshioka M, Hancock BC, Zografi G. (1995). Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. J Pharm Sci, 84:983.
   PubMed Web of Science ®Google Scholar